27 March 2018 - Deborah Wilkes
Archived
GlaxoSmithKline is reviewing strategic options, including divestment, for Horlicks and its other consumer healthcare nutrition products. The company said the review would support funding of its proposed USD13.0 billion acquisition of Novartis' 36.5% stake in the consumer healthcare joint venture between the two companies.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.